share_log
Moomoo 24/7 ·  Apr 24 16:44
Acrivon Therapeutics Reports A 50% Confirmed Overall Response Rate Observed With ACR-368 In Oncosignature-Positive Gynecological Cancers; Initial Clinical Validation Of AP3 Patient Selection Platform, Demonstrated Ability To Prospectively Predict ACR-368 RECIST Responders
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment